A Phase 3 interventional study of Diroximel fumarate in Relapsing Forms of Multiple Sclerosis, sponsored by Biogen. Completed at 52 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-10-24.
Sponsored by Biogen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Multiple Sclerosis by Biogen — 2 open to participants now, 4 under way, 1 of them phase 3. Multiple Sclerosis · Biogen.
Among the 127 studies in Multiple Sclerosis by Biogen, this one is the 35th largest by enrollment of the 79 interventional ones that give a count, is one of 9 that started in 2021, is one of 28 in phase 3, and was the 116th registered.
3,269 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →2 of the 127 studies in Multiple Sclerosis by Biogen are open now, in 7 countries. Recruiting first, the newest first:
Biogen · Sites in United States, Australia, Germany and 4 more countries
Women only
Biogen
Ages 10–17
By country, each count listing its studies:
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 17 · Phase 3 29 · Phase 4 22
First in 1999; this study’s year is marked. 9 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 136 is above the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 110 across the 79 interventional studies, 355 across the 48 observational. Of the 119 that completed or were terminated, 36 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 127 studies in Multiple Sclerosis by Biogen, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are to determine the safety and tolerability of DRF administered for up to 24 weeks in adult East Asian participants with RMS (Part 1) and to determine the safety and tolerability of DRF administered for up to 48 weeks in adult East Asian participants with RMS (Part 2).
The secondary objective of this study is to evaluate the pharmacokinetic(s) (PK) of DRF metabolites (monomethyl fumarate [MMF] and 2-hydroxyethyl succinimide [HES]) following multiple doses of DRF in a subset of adult East Asian participants with RMS (Part 1).
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Japanese and Chinese participants will initiate treatment with DRF 231 milligrams (mg), oral capsule, twice daily on Day 1 through Day 7, followed by DRF 462 mg, oral capsules, twice daily from Day 8 up to Week 48.
Drug: Diroximel fumarate
Administered as specified in the treatment arm
Also known as: Vumerity, BIIB098, ALK8700
Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether/not related to the medicinal (investigational) product. An AE was considered treatment-emergent if it starts or worsens on or after the date of the first dose of study drug in the study until 1 day after the last dose of treatment, or completion of the safety follow-up visit, if applicable.(i.e. for participants who prematurely discontinued study treatment or withdrew from the study) . An SAE is any untoward medical occurrence that at any dose results in death, is a life-threatening event, requires inpatient hospitalization or prolongation of existing hospitalization, results in a significant disability/incapacity or congenital anomaly, is a medically important event. TEAEs included both serious and non-serious TEAEs.
Time frame: Baseline (Day 1) up to Week 24 (for prematurely discontinued participants, AEs were reported up to 2 weeks post discontinuation)
Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Laboratory Parameters
Laboratory assessments included hematology, blood chemistry, and urinalysis parameters. Hematology parameters:basophils, hematocrit, red blood cell, total and differential leukocytes, platelets, lymphocytes, monocytes, neutrophils, eosinophils, hemoglobin. Blood chemistry parameters:sodium, potassium, chloride, glucose, calcium, uric acid, total protein, albumin, creatine phosphokinase, Lipid profile: blood cholesterol,high-density lipoprotein,low-density lipoprotein, and triglycerides,serum follicle-stimulating hormone,Vitamin D,thyroid stimulating hormone,serum pregnancy, HIV/Hepatitis screen,tuberculosis test,alanine aminotransferase,aspartate aminotransferase,Lactate Dehydrogenase,alkaline phosphatase,gamma glutamyl transferase,total bilirubin,blood urea nitrogen,creatinine and bicarbonate. Urinalysis parameters:color,pH,specific gravity,ketones,protein,glucose, bilirubin,nitrite,urobilinogen,occult blood,microscopic examination,urine albumin,beta-2-microglobulin,urine creatinine.
Time frame: Baseline (Day 1) to Week 24
Part 1: Number of Participants With Abnormal Shift in 12-Lead Electrocardiogram (ECG) Values
The number of participants with shifts to categorical values of ECG interpretation (e.g. abnormal) were presented by each cohort. Abnormal shift includes a shift from normal or unknown to abnormal.
Time frame: Baseline (Day 1) to Week 24
Part 1: Number of Participants With Clinically Relevant Abnormalities in Vital Sign Parameters
Vital sign assessment included temperature, pulse rate systolic blood pressure, diastolic blood pressure, and respiratory rate. The criteria for determining potentially clinically relevant abnormalities in vital signs included: temperature \< 36 and \> 38 degrees Celsius (C), pulse rate \< 60 and \> 100 beats per minute (bpm), systolic blood pressure (\< 90, \> 140 and \> 160 millimeters of mercury \[mmHg\]), diastolic blood pressure \< 50, \> 90 and \> 100 mmHg, weight (7% or more increase from baseline, 7% or more decrease from baseline) and respiratory rate \< 12 and \> 20 breaths per minute.
Time frame: Baseline (Day 1) to Week 24
Part 1: Number of Participants With Columbia Suicide Severity Rating Scale (C-SSRS) Events
The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation, suicidal behavior and non-suicidal self-injurious behavior. The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, Suicidal behavior, completed suicide), suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan and intent) and non-suicidal self-injurious behavior.
Time frame: Baseline (Day 1) to Week 24
Parts 1 and 2: Number of Participants With TEAEs and TESAEs
An AE was any unfavorable and unintended sign, symptom, or disease temporally associated with use of medicinal (investigational) product, whether/not related to medicinal (investigational) product. AE was considered treatment-emergent if it starts or worsens on or after the date of the first dose of study drug in the study until 1 day after the last dose of treatment. SAE is any untoward medical occurrence that at any dose results in death, is a life-threatening event, requires inpatient hospitalization or prolongation of existing hospitalization, results in a significant disability/incapacity or congenital anomaly, is a medically important event. TEAEs included both serious and non-serious TEAEs. TEAEs and TESAEs for participants were collected cumulatively for Parts 1 and 2.
Time frame: From Day 1 up to the end of the study (up to Week 50)
Part 2: Number of Participants With Potentially Clinically Significant Abnormalities in Laboratory Parameters
Laboratory assessments included hematology, blood chemistry, and urinalysis parameters. Hematology parameters:basophils, hematocrit, red blood cell, total and differential leukocytes, platelets, lymphocytes, monocytes, neutrophils, eosinophils, hemoglobin. Blood chemistry parameters:sodium, potassium, chloride, glucose, calcium, uric acid, total protein, albumin, creatine phosphokinase, Lipid profile: blood cholesterol,high-density lipoprotein,low-density lipoprotein, and triglycerides,serum follicle-stimulating hormone,Vitamin D,thyroid stimulating hormone,serum pregnancy, HIV/Hepatitis screen,tuberculosis test,alanine aminotransferase,aspartate aminotransferase,Lactate Dehydrogenase,alkaline phosphatase,gamma glutamyl transferase,total bilirubin,blood urea nitrogen,creatinine and bicarbonate. Urinalysis parameters:color,pH,specific gravity,ketones,protein,glucose, bilirubin,nitrite,urobilinogen,occult blood,microscopic examination,urine albumin,beta-2-microglobulin,urine creatinine.
Time frame: Baseline (Day 1) to Week 48
Part 2: Number of Participants With Abnormal Shift in 12-Lead ECG Values
The number of participants with shifts to categorical values of ECG interpretation (e.g. abnormal) were presented by each cohort. Abnormal shift includes a shift from normal or unknown to abnormal.
Time frame: Baseline (Day 1) to Week 48
Part 2: Number of Participants With Clinically Relevant Abnormalities in Vital Sign Parameters
Vital sign assessment included temperature, pulse rate systolic blood pressure, diastolic blood pressure, and respiratory rate. The criteria for determining potentially clinically relevant abnormalities in vital signs included: temperature \< 36 and \> 38 degrees C, pulse rate \< 60 and \> 100 bpm, systolic blood pressure (\< 90, \> 140 and \> 160 mmHg), diastolic blood pressure \< 50, \> 90 and \> 100 mmHg, weight (7% or more increase from baseline, 7% or more decrease from baseline) and respiratory rate \< 12 and \> 20 breaths per minute.
Time frame: Baseline (Day 1) to Week 48
Part 2: Number of Participants With C-SSRS Events
The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation, suicidal behavior and non-suicidal self-injurious behavior. The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, Suicidal behavior, completed suicide), suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan and intent) and non-suicidal self-injurious behavior.
Time frame: Baseline (Day 1) to Week 48
Part 1: Plasma Concentrations of Monomethyl Fumarate (MMF)-Intensive Pharmacokinetic (PK) Analysis Set
Summarized data for plasma concentration of MMF at all timepoints is reported.
Time frame: Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169
Part 1: Plasma Concentration of 2-Hydroxyethyl Succinimide (HES)-Intensive PK Analysis Set
Summarized data for plasma concentration of HES at all timepoints is reported.
Time frame: Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169
Part 1: Plasma Concentrations of MMF-Sparse PK Analysis Set
Time frame: Pre-dose and 2 to 3 hours post-dose on Day 29 and Day 57
Part 1: Plasma Concentrations of HES-Sparse PK Analysis Set
Time frame: Pre-dose and 2 to 3 hours post-dose on Day 29 and Day 57
Part 1: Maximum Observed Concentration (Cmax) of MMF-Intensive PK Analysis Set
Summarized data for Cmax at all timepoints is reported.
Time frame: Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169
Part 1: Cmax of HES-Intensive PK Analysis Set
Summarized data for Cmax at all timepoints is reported.
Time frame: Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169
Part 1: Area Under the Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration (AUClast) of MMF-Intensive PK Analysis Set
Summarized data for AUClast at all timepoints is reported.
Time frame: Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169
Part 1: AUClast of HES-Intensive PK Analysis Set
Summarized data for AUClast at all timepoints is reported.
Time frame: Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169
Part 1: Time to Reach Cmax (Tmax) of MMF-Intensive PK Analysis Set
Summarized data for Tmax at all timepoints is reported.
Time frame: Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169
Part 1: Tmax of HES-Intensive PK Analysis Set
Summarized data for Tmax at all timepoints is reported.
Time frame: Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169
Part 1: Elimination Half-Life (t½) of MMF-Intensive PK Analysis Set
Summarized data for t½ at all timepoints is reported.
Time frame: Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169
Participants took part in the multiple investigative sites from 18 November 2021 to 11 September 2024.
| Milestone | Cohort 1: Japanese Participants | Cohort 2: Chinese Participants |
|---|---|---|
| Started | 52 | 50 |
| Completed | 47 | 40 |
| Not completed | 5 | 10 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Lack of efficacy | 1 | 3 |
| Withdrew: Withdrawal by subject | 2 | 6 |
| Withdrew: Reason not specified | 0 | 1 |
An adverse event (AE) was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether/not related to the medicinal (investigational) product. An AE was considered treatment-emergent if it starts or worsens on or after the date of the first dose of study drug in the study until 1 day after the last dose of treatment, or completion of the safety follow-up visit, if applicable.(i.e. for participants who prematurely discontinued study treatment or withdrew from the study) . An SAE is any untoward medical occurrence that at any dose results in death, is a life-threatening event, requires inpatient hospitalization or prolongation of existing hospitalization, results in a significant disability/incapacity or congenital anomaly, is a medically important event. TEAEs included both serious and non-serious TEAEs.
| Participants | Cohort 1: Japanese Participants | Cohort 2: Chinese Participants |
|---|---|---|
| TEAEs | 50 | 45 |
| TESAEs | 3 | 5 |
Laboratory assessments included hematology, blood chemistry, and urinalysis parameters. Hematology parameters:basophils, hematocrit, red blood cell, total and differential leukocytes, platelets, lymphocytes, monocytes, neutrophils, eosinophils, hemoglobin. Blood chemistry parameters:sodium, potassium, chloride, glucose, calcium, uric acid, total protein, albumin, creatine phosphokinase, Lipid profile: blood cholesterol,high-density lipoprotein,low-density lipoprotein, and triglycerides,serum follicle-stimulating hormone,Vitamin D,thyroid stimulating hormone,serum pregnancy, HIV/Hepatitis screen,tuberculosis test,alanine aminotransferase,aspartate aminotransferase,Lactate Dehydrogenase,alkaline phosphatase,gamma glutamyl transferase,total bilirubin,blood urea nitrogen,creatinine and bicarbonate. Urinalysis parameters:color,pH,specific gravity,ketones,protein,glucose, bilirubin,nitrite,urobilinogen,occult blood,microscopic examination,urine albumin,beta-2-microglobulin,urine creatinine.
| Participants | Cohort 1: Japanese Participants | Cohort 2: Chinese Participants |
|---|---|---|
| Leukocytes <=2.8 x 10^9 per liter (L) | 3 | 1 |
| Lymphocytes <0.91 x 10^9/L | 25 | 11 |
| Lymphocytes <0.8 x 10^9/L | 15 | 3 |
| Lymphocytes <0.5 x 10^9/L | 2 | 0 |
| Neutrophils <1.5 x 10^9/L | 5 | 2 |
| Neutrophils<1 x 10^9/L | 1 | 0 |
| Eosinophils >1.0 x 10^9/L | 7 | 0 |
| Hemoglobin <=95 gram per liter (g/L) for Female or <=115g/L for Male | 0 | 1 |
| Platelets <=75 x 10^9/L | 0 | 0 |
| Platelets >=700 x 10^9/L | 0 | 0 |
| Alanine Aminotransferase >=3 x upper limit of normal (ULN) | 7 | 3 |
| Alanine Aminotransferase >5 x ULN | 1 | 0 |
| Alanine Aminotransferase >10 x ULN | 0 | 0 |
| Aspartate Aminotransferase >=3 x ULN | 2 | 0 |
| Aspartate Aminotransferase >5 x ULN | 0 | 0 |
| Aspartate Aminotransferase >10 x ULN | 0 | 0 |
| Alkaline Phosphatase >3 x ULN | 0 | 0 |
| Alkaline Phosphatase >5 x ULN | 0 | 0 |
| Alkaline Phosphatase >10 x ULN | 0 | 0 |
| Gamma Glutamyl Transferase >=3 x ULN | 3 | 1 |
| Bilirubin >1.5 x ULN | 0 | 1 |
| Bilirubin >2 x ULN | 0 | 0 |
| Urea Nitrogen >10.71 Millimoles per Liter (mmol/L) | 0 | 0 |
| Creatinine >=176.8 Micromole per Litre (umol/L) | 0 | 0 |
| Bicarbonate <15 mmol/L | 0 | 0 |
| Bicarbonate >31 mmol/L | 0 | 0 |
| Ketones >=4+ | 1 | 0 |
| Protein >=2+ | 1 | 0 |
The number of participants with shifts to categorical values of ECG interpretation (e.g. abnormal) were presented by each cohort. Abnormal shift includes a shift from normal or unknown to abnormal.
| Participants | Cohort 1: Japanese Participants | Cohort 2: Chinese Participants |
|---|---|---|
| Part 1: Number of Participants With Abnormal Shift in 12-Lead Electrocardiogram (ECG) Values | 5 | 3 |
Vital sign assessment included temperature, pulse rate systolic blood pressure, diastolic blood pressure, and respiratory rate. The criteria for determining potentially clinically relevant abnormalities in vital signs included: temperature \< 36 and \> 38 degrees Celsius (C), pulse rate \< 60 and \> 100 beats per minute (bpm), systolic blood pressure (\< 90, \> 140 and \> 160 millimeters of mercury \[mmHg\]), diastolic blood pressure \< 50, \> 90 and \> 100 mmHg, weight (7% or more increase from baseline, 7% or more decrease from baseline) and respiratory rate \< 12 and \> 20 breaths per minute.
| Participants | Cohort 1: Japanese Participants | Cohort 2: Chinese Participants |
|---|---|---|
| Temperature <36 degrees C | 8 | 2 |
| Temperature >38 degrees C | 1 | 0 |
| Pulse Rate <60 bpm | 9 | 3 |
| Pulse Rate >100 bpm | 4 | 2 |
| Systolic Blood Pressure <90 mmHg | 4 | 1 |
| Systolic Blood Pressure >140 mmHg | 2 | 1 |
| Systolic Blood Pressure >160 mmHg | 0 | 1 |
| Diastolic Blood Pressure <50 mmHg | 2 | 0 |
| Diastolic Blood Pressure >90 mmHg | 13 | 4 |
| Diastolic Blood Pressure >100 mmHg | 2 | 0 |
| Weight 7% or more increase from baseline | 1 | 5 |
| Weight 7% or more decrease from baseline | 3 | 2 |
| Respiratory Rate <12 breaths/min | 3 | 0 |
| Respiratory Rate >20 breaths/min | 8 | 0 |
The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation, suicidal behavior and non-suicidal self-injurious behavior. The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, Suicidal behavior, completed suicide), suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan and intent) and non-suicidal self-injurious behavior.
| Participants | Cohort 1: Japanese Participants | Cohort 2: Chinese Participants |
|---|---|---|
| Suicidal Ideation | 0 | 1 |
| Suicidal Behavior | 0 | 0 |
| Non-suicidal Self-injurious Behavior | 0 | 0 |
An AE was any unfavorable and unintended sign, symptom, or disease temporally associated with use of medicinal (investigational) product, whether/not related to medicinal (investigational) product. AE was considered treatment-emergent if it starts or worsens on or after the date of the first dose of study drug in the study until 1 day after the last dose of treatment. SAE is any untoward medical occurrence that at any dose results in death, is a life-threatening event, requires inpatient hospitalization or prolongation of existing hospitalization, results in a significant disability/incapacity or congenital anomaly, is a medically important event. TEAEs included both serious and non-serious TEAEs. TEAEs and TESAEs for participants were collected cumulatively for Parts 1 and 2.
| Participants | Cohort 1: Japanese Participants | Cohort 2: Chinese Participants |
|---|---|---|
| TEAEs | 52 | 47 |
| TESAEs | 6 | 6 |
Laboratory assessments included hematology, blood chemistry, and urinalysis parameters. Hematology parameters:basophils, hematocrit, red blood cell, total and differential leukocytes, platelets, lymphocytes, monocytes, neutrophils, eosinophils, hemoglobin. Blood chemistry parameters:sodium, potassium, chloride, glucose, calcium, uric acid, total protein, albumin, creatine phosphokinase, Lipid profile: blood cholesterol,high-density lipoprotein,low-density lipoprotein, and triglycerides,serum follicle-stimulating hormone,Vitamin D,thyroid stimulating hormone,serum pregnancy, HIV/Hepatitis screen,tuberculosis test,alanine aminotransferase,aspartate aminotransferase,Lactate Dehydrogenase,alkaline phosphatase,gamma glutamyl transferase,total bilirubin,blood urea nitrogen,creatinine and bicarbonate. Urinalysis parameters:color,pH,specific gravity,ketones,protein,glucose, bilirubin,nitrite,urobilinogen,occult blood,microscopic examination,urine albumin,beta-2-microglobulin,urine creatinine.
| Participants | Cohort 1: Japanese Participants | Cohort 2: Chinese Participants |
|---|---|---|
| Leukocytes <=2.8 x 10^9/L | 6 | 3 |
| Lymphocytes <0.91 x 10^9/L | 28 | 16 |
| Lymphocytes <0.8 x 10^9/L | 20 | 11 |
| Lymphocytes <0.5 x 10^9/L | 5 | 1 |
| Neutrophils <1.5 x 10^9/L | 8 | 4 |
| Neutrophils <1 x 10^9/L | 2 | 2 |
| Eosinophils >1.0 x 10^9/L | 7 | 0 |
| Hemoglobin <=95g/L for Female or <=115g/L for Male | 3 | 2 |
| Platelets <=75 x 10^9/L | 0 | 0 |
| Platelets >=700 x 10^9/L | 0 | 0 |
| Alanine Aminotransferase >=3 x ULN | 7 | 4 |
| Alanine Aminotransferase >5 x ULN | 1 | 0 |
| Alanine Aminotransferase >10 x ULN | 0 | 0 |
| Aspartate Aminotransferase >=3 x ULN | 2 | 0 |
| Aspartate Aminotransferase >5 x ULN | 0 | 0 |
| Aspartate Aminotransferase >10 x ULN | 0 | 0 |
| Alkaline Phosphatase >3 x ULN | 0 | 0 |
| Alkaline Phosphatase >5 x ULN | 0 | 0 |
| Alkaline Phosphatase >10 x ULN | 0 | 0 |
| Gamma Glutamyl Transferase >=3 x ULN | 4 | 2 |
| Bilirubin >1.5 x ULN | 0 | 1 |
| Bilirubin >2 x ULN | 0 | 0 |
| Urea Nitrogen >10.71 mmol/L | 0 | 0 |
| Creatinine >=176.8 umol/L | 0 | 0 |
| Bicarbonate <15 mmol/L | 0 | 0 |
| Bicarbonate >31 mmol/L | 0 | 0 |
| Ketones >=4+ | 1 | 0 |
| Protein >=2+ | 3 | 0 |
The number of participants with shifts to categorical values of ECG interpretation (e.g. abnormal) were presented by each cohort. Abnormal shift includes a shift from normal or unknown to abnormal.
| Participants | Cohort 1: Japanese Participants | Cohort 2: Chinese Participants |
|---|---|---|
| Part 2: Number of Participants With Abnormal Shift in 12-Lead ECG Values | 7 | 5 |
Vital sign assessment included temperature, pulse rate systolic blood pressure, diastolic blood pressure, and respiratory rate. The criteria for determining potentially clinically relevant abnormalities in vital signs included: temperature \< 36 and \> 38 degrees C, pulse rate \< 60 and \> 100 bpm, systolic blood pressure (\< 90, \> 140 and \> 160 mmHg), diastolic blood pressure \< 50, \> 90 and \> 100 mmHg, weight (7% or more increase from baseline, 7% or more decrease from baseline) and respiratory rate \< 12 and \> 20 breaths per minute.
| Participants | Cohort 1: Japanese Participants | Cohort 2: Chinese Participants |
|---|---|---|
| Temperature <36 degrees C | 12 | 2 |
| Temperature >38 degrees C | 1 | 0 |
| Pulse Rate <60 bpm | 9 | 7 |
| Pulse Rate >100 bpm | 6 | 3 |
| Systolic Blood Pressure <90 mmHg | 7 | 2 |
| Systolic Blood Pressure >140 mmHg | 3 | 1 |
| Systolic Blood Pressure >160 mmHg | 0 | 1 |
| Diastolic Blood Pressure <50 mmHg | 3 | 1 |
| Diastolic Blood Pressure >90 mmHg | 14 | 5 |
| Diastolic Blood Pressure >100 mmHg | 4 | 0 |
| Weight 7% or more increase from baseline | 3 | 6 |
| Weight 7% or more decrease from baseline | 5 | 7 |
| Respiratory Rate <12 breaths/min | 6 | 0 |
| Respiratory Rate >20 breaths/min | 13 | 1 |
The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation, suicidal behavior and non-suicidal self-injurious behavior. The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, Suicidal behavior, completed suicide), suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan and intent) and non-suicidal self-injurious behavior.
| Participants | Cohort 1: Japanese Participants | Cohort 2: Chinese Participants |
|---|---|---|
| Suicidal Ideation | 0 | 2 |
| Suicidal Behavior | 0 | 0 |
| Non-suicidal Self-injurious Behavior | 0 | 0 |
Summarized data for plasma concentration of MMF at all timepoints is reported.
| Microgram per milliliter (ug/mL) | Cohort 1: Japanese Participants |
|---|---|
| Pre-dose | 0.1 ± 67.69 |
| 0.5 Hour Post-dose | 0.1 ± 37.55 |
| 1 Hour Post-dose | 0.1 ± 73.60 |
| 2 Hours Post-dose | 0.2 ± 184.48 |
| 3 Hours Post-dose | 0.5 ± 210.05 |
| 4 Hours Post-dose | 0.9 ± 63.43 |
| 6 Hours Post-dose | 0.4 ± 88.04 |
| 8 Hours Post-dose | 0.1 ± 58.32 |
Summarized data for plasma concentration of HES at all timepoints is reported.
| ug/mL | Cohort 1: Japanese Participants |
|---|---|
| Pre-dose | 9.0 ± 23.11 |
| 0.5 Hour Post-dose | 8.7 ± 23.59 |
| 1 Hour Post-dose | 8.4 ± 28.42 |
| 2 Hour Post-dose | 8.4 ± 30.88 |
| 3 Hour Post-dose | 9.5 ± 23.84 |
| 4 Hour Post-dose | 9.5 ± 31.92 |
| 6 Hour Post-dose | 9.9 ± 45.11 |
| 8 Hour Post-dose | 11.2 ± 26.05 |
| ug/mL | Cohort 1: Japanese Participants | Cohort 2: Chinese Participants |
|---|---|---|
| Day 29 (Pre-dose) | 0.1 ± 79.06 | 0.1 ± 144.66 |
| Day 29 (2-3 Hours Post-dose) | 0.9 ± 246.46 | 0.8 ± 223.71 |
| Day 57 (Pre-dose) | 0.1 ± 90.08 | 0.1 ± 91.21 |
| Day 57 (2-3 Hours Post-dose) | 0.7 ± 234.80 | 1.1 ± 131.05 |
| ug/mL | Cohort 1: Japanese Participants | Cohort 2: Chinese Participants |
|---|---|---|
| Day 29 (Pre-dose) | 8.2 ± 28.13 | 8.0 ± 32.54 |
| Day 29 (2-3 Hours Post-dose) | 9.1 ± 37.57 | 9.7 ± 38.05 |
| Day 57 (Pre-dose) | 8.4 ± 40.45 | 8.3 ± 34.97 |
| Day 57 (2-3 Hours Post-dose) | 9.5 ± 34.59 | 9.7 ± 31.27 |
Summarized data for Cmax at all timepoints is reported.
| ug/mL | Cohort 1: Japanese Participants |
|---|---|
| Part 1: Maximum Observed Concentration (Cmax) of MMF-Intensive PK Analysis Set | 1.2 ± 56.85 |
Summarized data for Cmax at all timepoints is reported.
| ug/mL | Cohort 1: Japanese Participants |
|---|---|
| Part 1: Cmax of HES-Intensive PK Analysis Set | 11.6 ± 26.49 |
Summarized data for AUClast at all timepoints is reported.
| hour*microgram per milliliter (h*ug/mL) | Cohort 1: Japanese Participants |
|---|---|
| Part 1: Area Under the Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration (AUClast) of MMF-Intensive PK Analysis Set | 3.6 ± 36.34 |
Summarized data for AUClast at all timepoints is reported.
| h*ug/mL | Cohort 1: Japanese Participants |
|---|---|
| Part 1: AUClast of HES-Intensive PK Analysis Set | 75.3 ± 29.31 |
Summarized data for Tmax at all timepoints is reported.
| hours | Cohort 1: Japanese Participants |
|---|---|
| Part 1: Time to Reach Cmax (Tmax) of MMF-Intensive PK Analysis Set | 3.8 (2 to 6) |
Summarized data for Tmax at all timepoints is reported.
| hours | Cohort 1: Japanese Participants |
|---|---|
| Part 1: Tmax of HES-Intensive PK Analysis Set | 5.80 (0.5 to 7.9) |
Summarized data for t½ at all timepoints is reported.
| hours | Cohort 1: Japanese Participants |
|---|---|
| Part 1: Elimination Half-Life (t½) of MMF-Intensive PK Analysis Set | 1.3 (0.8 to 1.3) |
Collected over From Day 1 up to the end of the study (up to Week 50). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Japanese Participants | 0/52 (0%) | 6/52 (11.5%) | 50/52 (96.2%) |
| Cohort 2: Chinese Participants | 0/50 (0%) | 6/50 (12%) | 42/50 (84%) |
| Event | Cohort 1: Japanese Participants | Cohort 2: Chinese Participants |
|---|---|---|
| Multiple sclerosis relapseNervous system disorders | 3/52 | 3/50 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/52 | 1/50 |
| DemyelinationNervous system disorders | 0/52 | 1/50 |
| Relapsing-remitting multiple sclerosisNervous system disorders | 0/52 | 1/50 |
| Staphylococcal bacteraemiaInfections and infestations | 1/52 | 0/50 |
| FallInjury, poisoning and procedural complications | 1/52 | 0/50 |
| Humerus fractureInjury, poisoning and procedural complications | 1/52 | 0/50 |
| Foot deformityMusculoskeletal and connective tissue disorders | 1/52 | 0/50 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/52 | 0/50 |
| Event | Cohort 1: Japanese Participants | Cohort 2: Chinese Participants |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 19/52 | 4/50 |
| Upper respiratory tract infectionInfections and infestations | 6/52 | 18/50 |
| FlushingVascular disorders | 17/52 | 9/50 |
| NasopharyngitisInfections and infestations | 11/52 | 2/50 |
| Covid-19Infections and infestations | 9/52 | 5/50 |
| Lymphocyte count decreasedInvestigations | 3/52 | 8/50 |
| PyrexiaGeneral disorders | 8/52 | 4/50 |
| Multiple sclerosis relapseNervous system disorders | 8/52 | 4/50 |
| PruritusSkin and subcutaneous tissue disorders | 3/52 | 7/50 |
| Weight decreasedInvestigations | 0/52 | 6/50 |
Safety analysis set included all participants who had received at least 1 dose of study treatment.
| Age, Continuous(years) | Cohort 1: Japanese Participants | Cohort 2: Chinese Participants | Total |
|---|---|---|---|
| Mean | 40.1 ± 9.56 | 35.6 ± 10.49 | 37.9 ± 10.23 |
| Sex: Female, Male(Participants) | Cohort 1: Japanese Participants | Cohort 2: Chinese Participants | Total |
|---|---|---|---|
| Female | 40 | 42 | 82 |
| Male | 12 | 8 | 20 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: Japanese Participants | Cohort 2: Chinese Participants | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 52 | 50 | 102 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1: Japanese Participants | Cohort 2: Chinese Participants | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 52 | 50 | 102 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Data sharing details ↗ · vivli.org
Ran from Nov 2021 to primary completion in Sep 2024, 33 months.
Results were first posted in Oct 2025, 1 year 1 month after primary completion.
Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 33 months is below that.
Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diroximel fumarate